Darlifarnib
Term · Oncology and biomedicine · MLC-T-ONC-012926
An orally bioavailable inhibitor of farnesyl transferase, with potential antineoplastic activity. Upon oral administration, darlifarnib targets, binds to and inhibits the enzyme farnesyl transferase. By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits Ras-dependent signaling and inhibits the proliferation of tumor cells in which Ras is overexpressed and/or mutated. Ras plays an important role in cell signaling, division and differentiation. Mutations of Ras may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.
| Identifier | MLC-T-ONC-012926 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | FTI KO-2806; farnesyl transferase inhibitor KO-2806 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012926",
"term": "Darlifarnib",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable inhibitor of farnesyl transferase, with potential antineoplastic activity. Upon oral administration, darlifarnib targets, binds to and inhibits the enzyme farnesyl transferase. By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits Ras-dependent signaling and inhibits the proliferation of tumor cells in which Ras is overexpressed and/or mutated. Ras plays an important role in cell signaling, division and differentiation. Mutations of Ras may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.",
"synonyms": [
"FTI KO-2806",
"farnesyl transferase inhibitor KO-2806"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/darlifarnib/"
}
Record 5,700 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.